Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director · CEO | June 29, 2026 | July 01, 2026 |
| Verve Therapeutics, Inc.VERV · Entity 11259 | Director | June 09, 2022 | June 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,047,205 |
Ending reported balance
After 2026-06-30 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-06-29 · Exercise / conversion · Acquired 18,663 · Balance 1,065,868 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 2 · 2026-06-29 · Exercise / conversion · Acquired 6,337 · Balance 1,072,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 3 · 2026-06-29 · Sale · Disposed 13,421 · Balance 1,058,784 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-06-29 · Sale · Disposed 11,579 · Balance 1,047,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2026-06-30 · Exercise / conversion · Acquired 25,000 · Balance 1,072,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 6 · 2026-06-30 · Sale · Disposed 23,100 · Balance 1,049,105 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 7 · 2026-06-30 · Sale · Disposed 1,900 · Balance 1,047,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2028-05-08 | Direct | 9 |
Reported balance
After 2026-06-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-06-29 · Exercise / conversion · Disposed 18,663 · Balance 9 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F6: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2028-07-13 | Direct | 230,804 |
Reported balance
After 2026-06-29 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-29 · Exercise / conversion · Disposed 6,337 · Balance 230,804 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2028-07-13 | Direct | 205,804 |
Reported balance
After 2026-06-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-06-30 · Exercise / conversion · Disposed 25,000 · Balance 205,804 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. |
| Common StockSEC Table I · non-derivative | IndirectBy John M. Evans, III 2018 Irrevocable Trust | 103,000 |
Reported balance
Holding disclosure · report date 2026-06-29 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 103,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.
Verve Therapeutics, Inc.
Report date June 09, 2022 · Filed June 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.04 · Expires 2032-06-08 | Direct | 15,500 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 15,500 · Balance 15,500 F1: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001193125-26-292526 · ownership.xml · derivative · entry 11 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,804 Underlying: Common Stock · 25,000 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F7 · derivative.exercise_date: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,900 | $34.84 | $66,203.03 |
DisclosureSEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,047,205 F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 23,100 | $34.26 | $791,482.23 |
DisclosureSEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,049,105 F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 25,000 | $1.03 | $25,750.00 |
DisclosureSEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,072,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,337 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001193125-26-292526 · ownership.xml · derivative · entry 10 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,804 Underlying: Common Stock · 6,337 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F7 · derivative.exercise_date: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,663 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001193125-26-292526 · ownership.xml · derivative · entry 9 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9 Underlying: Common Stock · 18,663 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F6 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 11,579 | $35.91 | $415,823.89 |
DisclosureSEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,047,205 F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 13,421 | $35.13 | $471,528.05 |
DisclosureSEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,058,784 F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 6,337 | $1.03 | $6,527.11 |
DisclosureSEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,072,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 18,663 | $0.67 | $12,504.21 |
DisclosureSEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,065,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Read SEC document |
| April 01, 2026 Filed Apr 6, 2026 21:48 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 30,078 | $24.58 | $739,317.24 |
DisclosureSEC source: 0001193125-26-144086 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,047,205 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023. F2 · balance_after: Includes 616 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001193125-26-138348 · ownership.xml · derivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,672 Underlying: Common Stock · 25,000 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F5 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-138348 · ownership.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,076,667 F4 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 25,000 | $22.76 | $569,085.00 |
DisclosureSEC source: 0001193125-26-138348 · ownership.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 986,667 F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.34 to $23.21, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 25,000 | $0.67 | $16,750.00 |
DisclosureSEC source: 0001193125-26-138348 · ownership.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,011,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001193125-26-138348 · ownership.xml · derivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,672 Underlying: Common Stock · 25,000 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F5 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 25,000 | $22.37 | $559,230.00 |
DisclosureSEC source: 0001193125-26-138348 · ownership.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 986,667 F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.03 to $22.70, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 25,000 | $0.67 | $16,750.00 |
DisclosureSEC source: 0001193125-26-138348 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,011,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $27.62 | $0.00 |
DisclosureSEC source: 0001193125-26-033600 · ownership.xml · derivative · entry 12 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2036-01-31 F7 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001193125-26-033600 · ownership.xml · derivative · entry 11 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,672 Underlying: Common Stock · 25,000 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F6 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,906 | $29.00 | $84,274.00 |
DisclosureSEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 986,667 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 22,094 | $28.27 | $624,672.50 |
DisclosureSEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 989,573 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $27.87 to $28.82 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 25,000 | $0.67 | $16,750.00 |
DisclosureSEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,011,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,664 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001193125-26-033600 · ownership.xml · derivative · entry 10 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,672 Underlying: Common Stock · 5,664 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F6 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,336 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001193125-26-033600 · ownership.xml · derivative · entry 9 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,336 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F5 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022, and December 31, 2022. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 8,667 | $29.74 | $257,780.85 |
DisclosureSEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 986,667 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $29.66 to $29.92 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 16,333 | $29.19 | $476,801.10 |
DisclosureSEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 995,334 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $28.65 to $29.64 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 5,664 | $0.67 | $3,794.88 |
DisclosureSEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,011,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 19,336 | $0.67 | $12,955.12 |
DisclosureSEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,006,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001193125-25-230084 · ownership.xml · derivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,336 Underlying: Common Stock · 25,000 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F5 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, June 30, 2022, and December 31, 2022. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 25,000 | $24.63 | $615,667.50 |
DisclosureSEC source: 0001193125-25-230084 · ownership.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 986,667 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.22 to $25.05, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 25,000 | $0.67 | $16,750.00 |
DisclosureSEC source: 0001193125-25-230084 · ownership.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,011,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001193125-25-230084 · ownership.xml · derivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,336 Underlying: Common Stock · 25,000 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F5 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, June 30, 2022, and December 31, 2022. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 25,000 | $24.51 | $612,655.00 |
DisclosureSEC source: 0001193125-25-230084 · ownership.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 986,667 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.14 to $24.92, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 25,000 | $0.67 | $16,750.00 |
DisclosureSEC source: 0001193125-25-230084 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,011,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F2 · balance_after: Includes 418 shares acquired by the Reporting Person under the Beam Therapeutics Inc. ("BEAM") Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 01:52 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 30,663 | $18.35 | $562,684.45 |
DisclosureSEC source: 0000950170-25-050857 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 986,249 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.38, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 753 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2025. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:10 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 77,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-049759 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,016,159 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0000950170-25-012304 · ownership.xml · derivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2035-01-31 F3 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 200 | $27.28 | $5,456.00 |
DisclosureSEC source: 0000950170-25-012304 · ownership.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 908,659 F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 29,800 | $26.75 | $797,027.82 |
DisclosureSEC source: 0000950170-25-012304 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 908,859 F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $26.26 to $27.21 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 30, 2025 Filed Apr 2, 2025 20:05 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000950170-25-049297 · ownership.xml · derivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,336 Underlying: Common Stock · 30,000 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On February 3, 2025, the Reporting Person filed a Form 4 (the "Original Form 4") that, among other things, reported the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan. The Original Form 4 inadvertently failed to disclose the exercise of derivative securities that occurred pursuant to the same Rule 10b5-1 trading plan, which occurred immediately prior to such sale. Accordingly, this Form 4/A is being filed to disclose the omitted transaction. Immediately following the transaction reported herein, the Reporting Person directly beneficially owned 968,659 shares of common stock of Beam Therapeutics Inc. F2 · security: (Continued from footnote 1) ("BEAM"), and accordingly, all disclosures of the amount of securities directly beneficially owned by the Reporting Person subsequent to the transaction reported herein and prior to the filing of this Form 4/A, including with respect to the transactions reported in the Original Form 4, should be deemed to be adjusted accordingly. As of the date the filing of this Form 4/A, the Reporting Person directly beneficially owns 938,659 shares of common stock of BEAM. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. F4 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,336 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Read SEC document |
| January 30, 2025 Filed Apr 2, 2025 20:05 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 30,000 | $0.67 | $20,100.00 |
DisclosureSEC source: 0000950170-25-049297 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 968,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On February 3, 2025, the Reporting Person filed a Form 4 (the "Original Form 4") that, among other things, reported the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan. The Original Form 4 inadvertently failed to disclose the exercise of derivative securities that occurred pursuant to the same Rule 10b5-1 trading plan, which occurred immediately prior to such sale. Accordingly, this Form 4/A is being filed to disclose the omitted transaction. Immediately following the transaction reported herein, the Reporting Person directly beneficially owned 968,659 shares of common stock of Beam Therapeutics Inc. F2 · security: (Continued from footnote 1) ("BEAM"), and accordingly, all disclosures of the amount of securities directly beneficially owned by the Reporting Person subsequent to the transaction reported herein and prior to the filing of this Form 4/A, including with respect to the transactions reported in the Original Form 4, should be deemed to be adjusted accordingly. As of the date the filing of this Form 4/A, the Reporting Person directly beneficially owns 938,659 shares of common stock of BEAM. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. F4 · balance_after: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,336 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 21:49 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 60,000 | $24.60 | $1,476,024.00 |
DisclosureSEC source: 0000950170-24-111732 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 938,659 F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.26 to $25.24, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 316 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2024. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:15 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 60,000 | $24.50 | $1,470,156.00 |
DisclosureSEC source: 0000950170-24-079065 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 998,343 F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.17 to $24.93, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 03, 2024 Filed Apr 3, 2024 23:36 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 53,965 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0000950170-24-041432 · ownership.xml · derivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,965 Underlying: Common Stock · 53,965 shares Expires 2029-02-13 F4 · derivative.exercise_date: On February 13, 2019, the Reporting Person was granted an option to purchase 53,965 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 53,965 shares. Read SEC document |
| April 03, 2024 Filed Apr 3, 2024 23:36 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 99,336 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000950170-24-041432 · ownership.xml · derivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,336 Underlying: Common Stock · 99,336 shares Expires 2028-05-08 F3 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase 99,336 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 23:36 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 18,102 | $32.13 | $581,617.26 |
DisclosureSEC source: 0000950170-24-041432 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,058,343 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.10 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2024 Filed Apr 1, 2024 20:10 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 77,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039319 · ownership.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,076,445 F3 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. F4 · balance_after: Includes 683 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2024. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:10 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 60,000 | $33.86 | $2,031,402.00 |
DisclosureSEC source: 0000950170-24-039319 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 998,262 F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.374 to $34.15, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $24.40 Strike: $24.40 | $3,782,000.00 |
DisclosureSEC source: 0000950170-24-010477 · ownership.xml · derivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2034-01-31 F4 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.